Supplementary Results
The linker for PROTAC_RIPK2, presented in the main text, was based on a previous generation of RIPK2 PROTACs utilizing the tyrosine kinase inhibitor vandetanib. The Structure-Activity Relationship for different linkers showed that the three PEG linker afforded maximal degradation. Based on these observations, the optimal linker (entry 2) was used in PROTAC_RIPK2. Targeting 
Supplementary Figure 8. Demonstration of a PROTAC-mediated ternary complex between RIPK2 and VHL
Immunoaffinity enrichment of endogenous VHL from THP-1 cell extract in the presence of RIPK2 inhibitor, PROTAC_RIPK2 and PROTAC_RIPK2_epi. Immunoblotting demonstrates enrichment of VHL (bottom) using an anti-VHL antibody as compared to IgG control. In the presence of various concentrations of PROTAC_RIPK2 but not with PROTAC_RIPK2_epi and RIPK2-binding ligand, RIPK2 is selectively co-precipitated (top). Shown are replicate n=1 and replicate n=2.
Supplementary Figure 9A. Kinome specificity of RIPK2 ligand
The specificity of the RIPK2 ligand was profiled against 371 kinases by KinoBead profiling (average of 2 determinations). 
